LRRK2

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Mittwoch, Mai 15, 2024
TWIST, IVDR, Partnership, Hereditary angioedema, DSM-IV codes, LRRK2, Genetic testing, Software, Cancer, Parkinsonism, Total, European, Drug discovery, RNA, Twist Bioscience, Disclosure, Mox, Niemann–Pick disease, CLN6, Sale, Whole genome sequencing, Publication, Epilepsy, Physician, Frontotemporal dementia, DNA sequencing, JV, CFTR, FTD, Elbow method (clustering), Disease, CNTG, Research, Observational study, Patient, Genetics, Gulf Cooperation Council, Sequence, CE, DNA, Therapy, Acyl-CoA, Software as a service, GCC, Growth, Gaucher's disease, Spinal muscular atrophy, Fine chemical

and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.
  • We expanded our partnership model with a joint venture in Saudi Arabia, securing a $30 million investment and additional milestone payments.
  • With this progress at the forefront, CENTOGENE is positioned for growth and a path towards profitability.
  • There can be no assurance that our strategic review process will result in any transaction or other strategic outcome.

Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer's Disease at Discovery Europe 2024

Retrieved on: 
Dienstag, Mai 14, 2024
Patient, Congress Center Basel, Basil, Hope, LRRK2, Discovery, LEHI, Impact, Neurodegenerative disease, Therapy, Conference, AI, Alzheimer's disease, Caregiver, Pathology, Drug discovery, Inflammation, RAB10, Pharmaceutical industry

David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland.

Key Points: 
  • David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland.
  • HT-4253 targets Leucine-Rich Repeat Kinase 2 (LRRK2) protein, which Halia has identified as a key player in regulating RAB10, a critical factor in the progression of Alzheimer's disease.
  • "As part of our participation, we are delighted to unveil and present data on our HT-4253 clinical program, representing a paradigm shift in Alzheimer's disease treatment.
  • For more information on the congress please visit: https://oxfordglobal.com/discovery/events/discovery-europe-2024
    Halia Therapeutics is unwavering in its commitment to advancing the HT-4253 program through rigorous clinical development.

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, Mai 7, 2024
Corporation, Sale, Greyhawk, License, Ribociclib, Palsy, HER2, General counsel, NVS, Food, ARVN, Research, Quantum Leap, Business development, Genentech, Development, Administration, Arm, Prostate cancer, Exercise, CDK7, Senior, Patient, Bayer, EOP, CDK4, Interim, PROTAC, LRRK2, Pharmaceutical industry

NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Announced the resignation of Chief Financial Officer and Treasurer, Sean Cassidy, effective February 29, 2024.
  • Research and Development Expenses: Research and development expenses were $84.3 million for the quarter ended March 31, 2024, as compared with $95.3 million for the quarter ended March 31, 2023.
  • General and Administrative Expenses: General and administrative expenses were $24.3 million for the quarter ended March 31, 2024, as compared with $24.9 million for the quarter ended March 31, 2023.
  • Revenues: Revenues were $25.3 million for the quarter ended March 31, 2024 as compared with $32.5 million for the quarter ended March 31, 2023.

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Montag, März 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference

Retrieved on: 
Montag, März 18, 2024
IPD, Brain, Conference, Disease, PD, CSF, Lung, OrbiMed, Traffic barrier, Parkinson's disease, LRRK2, Therapy, Safety, ACS, Kidney, Pharmaceutical industry

DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.

Key Points: 
  • DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.
  • Brenig's innovative approach to the rationally designed LRRK2 inhibitor (BT-0267) marks a significant stride in the company's mission to combat neurodegenerative diseases.
  • LRRK2, a key protein implicated in Parkinson's disease (PD), has been a challenging therapeutic target.
  • Current data highlights the superior safety profile of LRRK2 Inhibitor BT-0267 with an exceptional CSF to plasma ratio, in vivo efficacy of BT-0267 in brain and no visible lung and kidney morphological changes compared to other LRRK2 inhibitor candidates.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Dienstag, Februar 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, Februar 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

Retrieved on: 
Dienstag, Februar 20, 2024
Proteolysis, Traffic barrier, Senior, DSM-IV codes, Palsy, LRRK2, ARVN, Safety, Event, Biomarker, Pharmacokinetics, Patient, CHDR, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company’s first oral PROTAC® (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.

Key Points: 
  • In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase.
  • Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.
  • In non-human primates, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90%.
  • The Phase 1 clinical trial of ARV-102 is enrolling healthy volunteers at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.

Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation

Retrieved on: 
Dienstag, Februar 6, 2024
Intelligence, AI, Patient, LEHI, Alzheimer's disease, Leucine, Disease, Therapy, Drug development, LRRK2, Algorithm, Health, Iñaki, Medical device

LEHI, Utah, Feb. 6, 2024 /PRNewswire/ -- Halia Therapeutics, a pharmaceutical company at the forefront of developing neuroinflammation-targeting drugs, and Canary Speech, a leader in artificial intelligence vocal biomarker technology, today announced a collaboration to revolutionize the way Alzheimer's disease can be monitored and treated.

Key Points: 
  • This collaboration leverages Canary Speech's state-of-the-art AI vocal biomarker platform which utilizes advanced AI algorithms to analyze subtle changes in voice patterns and monitor cognitive function changes in Alzheimer's patients.
  • This non-invasive, efficient method offers a revolutionary approach to tracking the progression of Alzheimer's disease and the effectiveness of treatments.
  • "Canary AI-driven Speech technology will provide invaluable data to help us tailor our therapies more effectively and improve outcomes for patients with this debilitating neurodegenerative disease".
  • "We are thrilled to be combining our pioneering AI technology with Halia's' expertise in drug development targeting neuro-inflammation," said Henry O'Connell, CEO and Co-founder of Canary Speech.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Montag, Januar 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.